Houston-based Evolve Energy uses a subscription-based wholesale energy plan to help its customers find better prices for more sustainable resources. Photo via evolvemyenergy.com

A wholesale retail energy startup based in Houston is preparing to scale its artificial intelligence-backed business based on its positive customer feedback

Evolve Energy uses AI and machine learning to optimize energy usage, providing customers with the best wholesale energy prices on fluctuating renewable resources.

"We want to help our customers save a significant amount of money on electricity costs and help them decarbonize the grid," CEO Michael Lee tells InnovationMap."There's been a serious of emerging events that enable us to do both at the same time, it's no longer a choice."

Evolve Energy, founded in 2018, sells wholesale electricity at cost to residential customers in Texas, charging a $10 monthly subscription fee plus the cost of wholesale electricity. Using their AI technology, they predict when price surges are likely and determine how much energy the customer needs to hit the parameters set on the app by the customer and usage history. The customer does not need to do anything but pair Evolve with their smart thermostat.

According to Lee, this enables customers to continue to use the same volume of electricity but cut their bill by 40 percent over the course of a year. Evolve uses a different business model, positioning itself not as energy providers but as efficient energy managers, passing their wholesale rate with no markup for even more savings to the customer.

"It builds a lot of trust between the customer and the supplier, they truly see that our incentive is to save them money and not to sell them any more power," Lee says.

With the increasing trend of electrification, Lee sees the role of energy companies grow in importance. This gives energy managers like Evolve a magnified role as machine learning and AI becomes imperative to shift consumption when renewables are cheaper on the grid.

Evolve is backed by several investors including Matt Rogers, the original co-founder of Nest thermostats through his investment platform, Incite; Urban-X funded by BMW MINI which focuses on smart applications; and the Austin-based startup accelerator and investor, Capital Factory.

The company has been officially on the market for the past two months, but it's already working on deploying capital to build in features requested by customers. Evolve expects significant growth in the next few years due to its highly scalable model.

"I'm just glad we could create a product that no longer makes it a choice between reducing emissions and saving money," Lee says.

Houston-based Innowatts closed its Series B funding round — a $18.2 million commitment from the likes of Energy Impact Partners, Shell Ventures, and more. Photo via innowattts.com

Houston AI-enabled retail energy platform receives $18.2M investment

Follow the money

Houston-based Innowatts has closed its Series B funding round lead by Energy Impact Partners. The company, which enables artificial intelligence through its retail energy technology platform, secured a $18.2 million investment. Current funders also include Shell Ventures, Iberdrola, and Energy and Environment Investment (EEI Japan) — which all three supported the company in its Series A — along with new investor Evergy Ventures.

The funds will be used to grow the company's eUtilityTMplatform technology — a B2B cloud-based software tool to help retail energy providers better deliver quality energy services and insights to clients. The eUtilityTM platform already processes meter data from over 21 million customers globally and across 13 regional energy markets, according to the release.

"Competing in today's complex and evolving marketplace requires utility companies use data and intelligence to drive business and customer value," says Siddhartha Sachdeva, founder and CEO of Innowatts, in a release. "Energy Impact Partners, along with its coalition of innovative utility investors, appreciates the role that the eUtilityTM platform can play in creating a smarter, more efficient energy value chain. We're excited to have EIP join us on the next phase of our journey in building the digital utility of the future."

The company is "poised to become a key building block in the software-driven, intelligent grid of the future," says Michael Donnelly, partner and chief risk officer at EIP in the release.

"We invest in companies driving the transformation of the energy sector towards an increasingly decarbonized, digitized, and electrified future – solutions that our utility partners can commercialize at scale and have the greatest impact," Donnelly continues.

Innowatts' $6 million Series A round closed in August 2017. Shell Ventures lead that round.

"Utilities have the opportunity to deliver more value to customers, at lower costs and with greater personalization than ever before, while helping streamline the complex energy marketplace," says Geert van de Wouw, vice president Shell Ventures, in a release. "The predictive customer intelligence and digital solutions provided by Innowatts' eUtilityTM platform is central to executing that vision."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”